Phase I Study of a Novel Oral Janus Kinase 2 Inhibitor, SB1518, in Patients With Relapsed Lymphoma: Evidence of Clinical and Biologic Activity in Multiple Lymphoma Subtypes

PURPOSE: The Janus kinase 2/signal transducers and activators of transcription (JAK2/STAT) pathway plays an important role in the pathogenesis of hematologic malignancies. We conducted a phase I dose-finding and pharmacokinetic/pharmacodynamic study of SB1518, a potent JAK2 inhibitor, in patients wi...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:J Clin Oncol
Autores principales: Younes, Anas, Romaguera, Jorge, Fanale, Michelle, McLaughlin, Peter, Hagemeister, Frederick, Copeland, Amanda, Neelapu, Sattva, Kwak, Larry, Shah, Jatin, de Castro Faria, Silvana, Hart, Stefan, Wood, Jeanette, Jayaraman, Ramesh, Ethirajulu, Kantharaj, Zhu, Joy
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society of Clinical Oncology 2012
Materias:
ORIGINAL REPORTS
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5950499/
https://ncbi.nlm.nih.gov/pubmed/22965964
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2012.42.5223
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares